BioCentury | Feb 28, 2020
Product Development

NIH, Hubei trials of remdesivir could be more telling than Gilead’s

A look at the five Phase II and III clinical trials testing remdesivir to treat COVID-19 suggests the Gilead-sponsored trials may be less informative about efficacy. Three different organizations are sponsoring the studies. NIH’s adaptive...
BioCentury | Feb 15, 2020
Product Development

Preclinical potencies of clinical COVID-19 candidates

Among the several dozen agents in clinical testing for COVID-19, in vitro data against the new coronavirus have only been reported for four, and they support the WHO’s prioritization of remdesivir from Gilead Sciences Inc....
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

Myriad misses Street as CEO Capone departs Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting fiscal 2Q20 EPS and revenues that missed consensus estimates and announcing the departure of President and CEO...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Feb 5, 2020
Product Development

WHO prioritizing Gilead’s remdesivir, designing master protocol for 2019-nCoV outbreak

Gilead’s remdesivir is the most promising candidate for treating 2019-nCoV acute respiratory disease, according to a draft report of WHO’s R&D Blueprint Clinical Trials expert group. The group agreed in principle to design a randomized,...
BC Extra | Jan 29, 2020
Preclinical News

Rosenberg study highlights opportunity for blood-based take on TILs against mutant p53

A new study from TIL pioneer Steve Rosenberg adds to the momentum of blood-derived personalized T cell therapies by showing concordance between T cell responses against common p53 mutations in patients’ solid tumors and those...
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

A series of follow-ons pushed biotechs to raise about $1.5 billion this week, bringing January's total raise to about $2.6 billion via 16 follow-ons. The offerings have already outpaced last January, which saw $1.7 billion...
Items per page:
1 - 10 of 416